Bacterial infections in cirrhosis: Role of proton pump inhibitors and intestinal permeability

European Journal of Clinical Investigation

Volumn 42, Issue 7, 2012, Pages 760-767

  van Vlerken, Lotte G ^a   Huisman, Ellen J ^a   van Hoek, Bart ^b   Renooij, Willem ^a   de Rooij, Felix W M ^c   Siersema, Peter D ^a   Van Erpecum, Karel J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Acid suppressive therapy; Bacterial infection; Bacterial overgrowth; Intestinal permeability; Proton pump inhibitors; Spontaneous bacterial peritonitis

Indexed keywords

MACROGOL; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL INFECTION; BACTERIAL OVERGROWTH; CONTROLLED STUDY; DRUG MEGADOSE; ESOPHAGOJEJUNOSTOMY; FEMALE; FOLLOW UP; GASTRECTOMY; HUMAN; INFECTION RISK; INTESTINE MUCOSA PERMEABILITY; JEJUNUM; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; ANIMALS; BACTERIA; BACTERIAL INFECTIONS; COHORT STUDIES; FEMALE; HUMANS; JEJUNUM; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MODELS, ANIMAL; NETHERLANDS; OMEPRAZOLE; PERITONITIS; PERMEABILITY; POLYETHYLENE GLYCOLS; PROTON PUMP INHIBITORS; RANITIDINE; RATS; RATS, WISTAR; RISK FACTORS;

EID: 84862634309     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2011.02643.x     Document Type: Article

References (34)

1. Christou L, Pappas G, Falagas ME. Bacterial infection-related morbidity and mortality in cirrhosis. Am J Gastroenterol 2007;102:1510-7.
2. Borzio M, Salerno F, Piantoni L, Cazzaniga M, Angeli P, Bissoli F et al. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis 2001;33:41-8.
3. Fernandez J, Navasa M, Gomez J, Colmenero J, Vila J, Arroyo V et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002;35:140-8.
4. Merli M, Lucidi C, Giannelli V, Giusto M, Riggio O, Falcone M et al. Cirrhotic patients are at risk for health care-associated bacterial infections. Clin Gastroenterol Hepatol 2010;8:979-85.
5. Arvaniti V, D'Amico G, Fede G, Manousou P, Tsochatzis E, Pleguezuelo M et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 2010;139:1246-56.
6. Bauer TM, Steinbruckner B, Brinkmann FE, Ditzen AK, Schwacha H, Aponte JJ et al. Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis. Am J Gastroenterol 2001;96:2962-7.
7. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005;41:422-33.
8. Ersoz G, Aydin A, Erdem S, Yuksel D, Akarca U, Kumanlioglu K. Intestinal permeability in liver cirrhosis. Eur J Gastroenterol Hepatol 1999;11:409-12.
9. Scarpellini E, Valenza V, Gabrielli M, Lauritano EC, Perotti G, Merra G et al. Intestinal permeability in cirrhotic patients with and without spontaneous bacterial peritonitis: is the ring closed? Am J Gastroenterol 2010;105:323-7.
10. Cariello R, Federico A, Sapone A, Tuccillo C, Scialdone VR, Tiso A et al. Intestinal permeability in patients with chronic liver diseases: its relationship with the aetiology and the entity of liver damage. Dig Liver Dis 2010;42:200-4.
11. Fiuza C, Salcedo M, Clemente G, Tellado JM. In vivo neutrophil dysfunction in cirrhotic patients with advanced liver disease. J Infect Dis 2000;182:526-33.
12. Rimola A, Soto R, Bory F, Arroyo V, Piera C, Rodes J. Reticuloendothelial system phagocytic activity in cirrhosis and its relation to bacterial infections and prognosis. Hepatology 1984;4:53-8.
13. Driks MR, Craven DE, Celli BR, Manning M, Burke RA, Garvin GM et al. Nosocomial pneumonia in intubated patients given sucralfate as compared with antacids or histamine type 2 blockers. The role of gastric colonization. N Engl J Med 1987;317:1376-82.
14. Johnstone J, Nerenberg K, Loeb M. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. Aliment Pharmacol Ther 2010;31:1165-77.
15. Bajaj JS, Zadvornova Y, Heuman DM, Hafeezullah M, Hoffmann RG, Sanyal AJ et al. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am J Gastroenterol 2009;104:1130-4.
16. Campbell MS, Obstein K, Reddy KR, Yang YX. Association between proton pump inhibitor use and spontaneous bacterial peritonitis. Dig Dis Sci 2008;53:394-8.
17. Choi EJ, Lee HJ, Kim KO, Lee SH, Eun JR, Jang BI et al. Association between acid suppressive therapy and spontaneous bacterial peritonitis in cirrhotic patients with ascites. Scand J Gastroenterol 2011;46:616-20.
18. Trikudanathan G, Israel J, Cappa J, O'Sullivan DM. Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients - a systematic review and meta-analysis. Int J Clin Pract 2011;65:674-8.
19. Reisner BS, Woods GL, Thomson RB Jr, Larone DH, Garcia LS, Shimizu RY. General issues in clinical microbiology: general processing. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, editors. Manual of Clinical Microbiology, 7th edn. Washington, DC, USA: ASM Press; 1999: pp 64-104.
20. Huisman EJ, Trip E, van Hoek B, Siersema PD, van Erpecum KJ. Protein energy malnutrition predicts complications in liver cirrhosis. Eur J Gastroenterol Hepatol 2011;23:982-9.
21. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929-38.
22. Rimola A, Garcia-Tsao G, Navasa M, Piddock LJ, Planas R, Bernard B et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol 2000;32:142-53.
23. Runyon BA. Management of adult patients with ascites due to cirrhosis. Hepatology 2004;39:841-56.
24. Parlesak A, Bode JC, Bode C. Parallel determination of gut permeability in man with M(r) 400, M(r) 1500, M(r) 4000 and M(r) 10, 000 polyethylene glycol. Eur J Clin Chem Clin Biochem 1994;32:813-20.
25. Parlesak A, Schafer C, Schutz T, Bode JC, Bode C. Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. J Hepatol 2000;32:742-7.
26. Ammori BJ, Fitzgerald P, Hawkey P, McMahon MJ. The early increase in intestinal permeability and systemic endotoxin exposure in patients with severe acute pancreatitis is not associated with systemic bacterial translocation: molecular investigation of microbial DNA in the blood. Pancreas 2003;26:18-22.
27. Ammori BJ, Leeder PC, King RF, Barclay GR, Martin IG, Larvin M et al. Early increase in intestinal permeability in patients with severe acute pancreatitis: correlation with endotoxemia, organ failure, and mortality. J Gastrointest Surg 1999;3:252-62.
28. Kerckhoffs AP, Akkermans LM, de Smet MB, Besselink MG, Hietbrink F, Bartelink IH et al. Intestinal permeability in irritable bowel syndrome patients: effects of NSAIDs. Dig Dis Sci 2010;55:716-23.
29. Besselink MG, van Santvoort HC, Renooij W, de Smet MB, Boermeester MA, Fischer K et al. Intestinal barrier dysfunction in a randomized trial of a specific probiotic composition in acute pancreatitis. Ann Surg 2009;250:712-9.
30. Dial MS. Proton pump inhibitor use and enteric infections. Am J Gastroenterol 2009;104(Suppl 2):S10-6.
31. Chang CS, Chen GH, Lien HC, Yeh HZ. Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 1998;28:1187-90.
32. Chesta J, Defilippi C, Defilippi C. Abnormalities in proximal small bowel motility in patients with cirrhosis. Hepatology 1993;17:828-32.
33. Pande C, Kumar A, Sarin SK. Small-intestinal bacterial overgrowth in cirrhosis is related to the severity of liver disease. Aliment Pharmacol Ther 2009;29:1273-81.
34. Pardo A, Bartoli R, Lorenzo-Zuniga V, Planas R, Vinado B, Riba J et al. Effect of cisapride on intestinal bacterial overgrowth and bacterial translocation in cirrhosis. Hepatology 2000;31:858-63.